Tests help physicians determine patient's individual risk for metastasis

IRVINE, California – Agendia, a world leader in molecular cancer diagnostics, announced that results from five studies focused on breast, colon and colorectal cancer will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31-June 4, 2013 at McCormick Place in Chicago. Of particular importance are the studies which demonstrate that molecular subtyping allows for improvement in therapy selection and overall patient survival. 

Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products. Its breast cancer Symphony? suite was developed by analyzing the complete human genome, ensuring 100% definitive results for cancer patients. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

The posters covering breast cancer include:

- Effectiveness of MammaPrint? and BluePrint? in identifying molecular subtypes of breast tumors as a predictor for tumor response to targeted chemotherapies;

- MammaPrint MINT study assesses the ability of molecular profiling and traditional pathologic and clinical prognostic factors to predict patient response to neo-adjuvant chemotherapy; and

- Genomic profiling of breast cancer in African American women.

"It is clear that molecular subtypes are key pieces of information in determining the best course of treatment for breast cancer patients, and that subtyping will only become more important as hundreds of targeted therapies reach the market in the coming decade," said Agendia CEO David Macdonald .

The posters/discussions covering colorectal and colon cancer include:

- Intrinsic subtypes of colorectal cancer that direct different treatment strategies.

- The use of ColoPrint? as a predictor of outcome and chemotherapy benefit in stage II and III colon cancer patients.

"Like breast cancer, where molecular classificLebron XIII EP Glow